

Supplementary




Figure S1 Outcome of patients with PVT who underwent LT. (A) Kaplan-Meier OS after LT for patients with complex PVT and non-complex PVT. (B) The correlation between non-PHT related postoperative complications with OS after LT. PVT, portal vein thrombosis; LT, liver transplantation; OS, overall survival; PHT, portal hypertension.




Figure S2 Dynamic changes of liver function and renal function on day 1, 3, 5, 7, 14 after LT. (A) ALT level. (B) AST level. (C) Total bilirubin level. (D) Creatinine level. LT, liver transplantation; PVT, portal vein thrombosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase.




Figure S3 Patient who received RPA and SPA simultaneously. (A) renoportal anastomosis. (B) portal vein and splenic vein anastomosis. RPA, renoportal anastomosis; SPA, splenic-portal anastomosis; PV, portal vein; LRV, left renal vein.




Figure S4 Patient who received RPA and CPA simultaneously. (A) renoportal anastomosis. (B) coronary-portal anastomosis. RPA, renoportal anastomosis; CPA, coronary-portal anastomosis; PV, portal vein; LRV, left renal vein; LGV, left gastric vein; IVC, inferior vena cava.




Figure S5 Proposed flowchart for the management of complex portal vein thrombosis in liver transplantation.

Table S1 Operative details and postoperative course of patients with complex PVT

Patient no.	PVT grade	Sex/age (yr)	Pretransplant portosystemic shunt	Portal reconstruction	Interposed graft	Operative time (minutes)	RBC transfusion (units)	Anastomotic thrombosis	Anastomotic stricture	Postoperative complication related to PHT	Postoperative complication not related to PHT	Outcome/OS (m)
1	Yerdel 4	M/59	LGV	CPA	None	285	9	None	None	None	GVHD	Died due to GVHD/0.97 m
2	Yerdel 4	M/46	LGV	CPA	Yes	410	9	None	None	None	None	Alive/25.1 m
3	Yerdel 4	F/53	LGV	CPA	None	240	7	None	None	None	Biliary stenosis	Alive/42.4 m
4	Yerdel 4	F/53	LGV	CPA	None	382	14	None	None	None	None	Alive/32.6 m
5	Yerdel 4	M/56	LGV	CPA	None	320	18	None	None	None	Pulmonary hypertension	Died due to pulmonary hypertension/3.6 m
6	Yerdel 4	M/34	LGV	CPA	None	411	11	None	None	None	None	Alive/40.2 m
7	Yerdel 4	M/53	LGV	CPA	None	292	10	None	Yes	None	Biliary bleeding	Alive/10.3 m
8	Yerdel 4	M/53	pericholedochal varix	pericholedochal varix to portal anastomosis	None	360	0	None	None	None	None	Alive/23.6 m
9	Yerdel 4	M/50	SV	SPA	Yes	515	13	None	None	None	Biliary stenosis	Alive/13.8 m
10	Yerdel 4	F/32	DSMV	DSMV to portal anastomosis	Yes	426	12	None	Yes	None	Biliary stenosis	Alive/16.1 m
11	Yerdel 4	M/52	SRS, SV	RPA and SPA	Yes	375	2	None	None	None	None	Alive/11.1 m
12	Yerdel 4	F/17	SRS	RPA	None	319	6	None	Yes	None	None	Alive/7.0 m
13	Yerdel 4	M/39	SRS	RPA	Yes	380	0	None	None	None	None	Alive/14.1 m
14	Yerdel 4	F/50	SRS, LGV	RPA and CPA	Yes	427	14	Yes	Yes	None	None	Alive/8.6 m
15	Yerdel 4	M/50	SRS, IMV	RPA and IPA	Yes	295	4	None	None	None	None	Alive/17.6 m
16	Yerdel 4	M/55	SRS	RPA	None	420	18	None	None	None	Biliary stenosis and infection	Died due to infection/1.9 m

PVT, portal vein thrombosis; RBC, red blood cell; PHT, portal hypertension; OS, overall survival; RPA, renoportal anastomosis; CPA, coronary-portal anastomosis; LGV, left gastric vein; SRS, splenorenal shunt; SV, splenic vein; DSMV, distal superior mesenteric vein; SPA, splenic-portal anastomosis; IMV, inferior mesenteric vein; IPA, IMV-portal anastomosis; GVHD, graft versus host disease.